Status
Conditions
Treatments
About
The goal of this study is to compare the effect of different ways to place the component that goes at the top of the humerus (upper arm) in reverse total shoulder replacement. Some surgeons place the humeral tray component sitting on the bone while others place it in the bone. Changing the way that the humeral component is placed may change how much the arm can raise up or turn out/in after surgery for some patients. This study compares patients with inlay humeral component (tray sits in the upper arm bone) versus onlay humeral component (tray sits on top of the upper arm bone) to see if there are differences in range of motion or function after surgery.
Full description
This study aims to determine if active external rotation two years postoperatively varies based on whether an inlay or onlay humeral component is used in reverse shoulder arthroplasty (RTSA). The study also aims to determine whether active forward elevation, abduction, scapular notching, and functional outcomes two years postoperatively vary based on whether an inlay or onlay humeral component is used in reverse shoulder arthroplasty. Patients undergoing primary RTSA by Dr. J. Michael Wiater, Dr. Brett Wiater, or Dr. Alexander Martusiewicz at Beaumont Health will be screened for eligibility. Following informed consent, participants will be randomised (1:1) to one of the following groups: 1) RTSA with inlay humeral component (Tornier Perform Stem Reverse+) or 2) RTSA with onlay humeral component (Tornier Ascend Flex stem). At baseline, participants will complete study questionnaires, receive a range-of-motion (ROM) exam, and standard of care x-rays and computed tomography (CT) scans. These evaluations will be repeated at 3 months, 12 months and 24 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients undergoing primary reverse total shoulder arthroplasty with the following components:
Diagnosis of cuff tear arthropathy, massive cuff tear, or primary osteoarthritis with cuff tear
Negative external rotation lag sign, ability to externally rotate beyond neutral
Age 18 years or older
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
154 participants in 2 patient groups
Loading...
Central trial contact
Grace SanAgustin, BSN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal